Science and pragmatism in the treatment and prevention of neutropenic infection

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. D, 1998, Pages 13-24

  Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MYCOSIS; NEUTROPENIA; REVIEW;

EID: 0031801068     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_4.13     Document Type: Review

References (65)

1. Brown, P. K. (1992). In Histoire Illustrée de l'Hématologie de l'Antiquitée à Nos Jours. (Bernard, J., Bessi, M. & Binet, J. L., Eds) Editions R. Dacosta, Paris.
2. Schultz, W. (1992). In: (Bernard, J., Bessi, M. & Binet, J. L., Eds) Histoire Illustrée de l'Hématologie de l'Antiquitée à Nos Jours. Editions R. Dacosta, Paris.
3. Bodey, G. P., Buckley, M., Sathe, Y. S. & Freireich, F. J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 64, 328-40.
4. McCabe, W. R. & Jackson, G. G. (1962). Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Archives of Internal Medicine 110, 856-64.
5. Bodey, G. P., Middleman, E., Umsawadi, T. & Rodriguez, V. (1972). Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer 29, 1697-701.
6. Sickles, E. A., Greene, W. H. & Wiernik, P. H. (1975). Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 135, 715-9.
7. Schimpff, S., Satterlee, W., Young, V. M. & Serpick, A. (1971). Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. New England Journal of Medicine 284, 1061-5.
8. EORTC International Antimicrobial Therapy Cooperative Group. (1993). Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Annals of Internal Medicine 119, 584-93.
9. Cometta, A., Zinner, S., de Bock, R., Calandra, T., Gaya, H., Klastersky, J. et al. (1995). Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 39, 445-52.
10. Klastersky, J., Daneau, D., Swings, G. & Weerts, D. (1974). Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. Journal of Infectious Diseases 129, 187-93.
11. EORTC International Antimicrobial Therapy Cooperative Group. (1987). Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. New England Journal of Medicine 317, 1692-8.
12. EORTC International Antimicrobial Therapy Project Group. (1978). Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. Journal of Infectious Diseases 137, 14-29.
13. Klastersky, J., Glauser, M. P., Schimpff, S. C., Zinner, S. H., Gaya, H. & the European Organization for Research on Treatment of Cancer Antimicrobial Therapy Group. (1986). Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrobial Agents and Chemotherapy 29, 263-70.
14. Karp, J. E., Dick, J. D., Angelopulos, C., Charache, P., Green, L., Burke, P. J. et al. (1986). Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. American Journal of Medicine 81, 237-42.
15. Shenep, J. L., Hughes, W. T., Robertson, P. K., Blankenship K. R., Baker, D. K., Meyer, W. H. et al. (1988). Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. New England Journal of Medicine 319, 1053-8.
16. EORTC International Antimicrobial Therapy Cooperative Group. (1991). Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. Journal of Infectious Diseases 163, 951-8.
17. Rubin, M., Hathorn, J. W., Marshall, D., Gress, J., Steinberg, S. M. & Pizzo, P. A. (1988). Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Annals of Internal Medicine 108, 30-5.
18. Awada, A., Van der Auwera, P., Meunier, F., Daneau, D. & Klastersky, J. (1992). Streptococcal and enterococcal bacteremia in patients with cancer. Clinical Infectious Diseases 15, 33-48.
19. Attal, M., Schlaifer, D., Rubie, H., Huguet, F., Charlet, J.-P., Bloom, E. et al. (1991). Prevention of Gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. Journal of Clinical Oncology 9, 865-70.
20. Lamy, T., Michelet, C., Dauriac, C., Grulois, I., Donio, P.-Y. & Le Prisé, P.-Y. (1993). Benefit of prophylaxis by intravenous systemic vancomycin in granulocytopenic patients: a prospective, randomized trial among 59 patients. Acta Haematologica 90, 109-13.
21. Klastersky, J. (1993). Febrile neutropenia. Current Opinion in Oncology 5, 625-32.
22. EORTC International Antimicrobial Therapy Cooperative Group. (1984). Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. Journal of Infectious Diseases 150, 372-9.
23. EORTC International Antimicrobial Therapy Cooperative Group. (1994). Reduction of fever and Streptococcal bacteremia in granulocytopenic patients with cancer. Journal of the American Medical Association 272, 1183-9.
24. Ball, P. (1995). Editorial response: is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? Clinical Infectious Disease 20, 561-3.
25. Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W. & Lietman, P. S. (1981). Acyclovir prophylaxis of herpes-simplexvirus infections. New England Journal of Medicine 305, 63-7.
26. Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H. et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 326, 845-51.
27. Beyer, J., Barzen, G., Risse, G., Weyer, C., Miksits, K., Dullenkopf, K. et al. (1993). Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 37, 1367-9.
28. O'Connell, M. R., Schmidt, G. M., Tegtmeier, B. R., Faucett, C., Fahey, J. L., Ito, J. et al. (1994). Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. Journal of Clinical Oncology 12, 827-34.
29. Goodrich, J. M., Mori, M., Gleaves, C. A., Du Mond, C., Cays, M., Ebeling, D. F. et al. (1991). Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New England Journal of Medicine 325, 1601-7.
30. Broun, E. R., Wheat, J. L., Kneebone, P. H., Sundblad, K., Hromas, R. A. & Tricot, G. (1994). Randomized trial of the addition of Gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrobial Agents and Chemotherapy 38, 576-9.
31. Karp, J. E., Merz, W. G., Hendricksen, C., Laughton, B., Redden, T., Bamberger, B. J. et al. (1987). Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 106, 1-7.
32. Sculier, J. P., Weerts, D. & Klastersky, J. (1984). Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. European Journal of Cancer and Clinical Oncology 20, 55-60.
33. Rossi, C. & Klastersky, J. (1996). Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death. Supportive Care in Cancer 4, 207-12.
34. EORTC International Antimicrobial Therapy Cooperative Group and the GIMEMA Infection Program. (1995). Meropem versus ceftazidime plus amikacin as empirical therapy for fever in cancer patients with granulocytopenia. Canadian Journal of Infectious Diseases 6, Suppl. C, 308, Abstract 1083.
35. Pizzo, P. A., Hathorn, J. W., Hiemenz, J., Browne, M., Commers, J., Cotton, D. et al. (1986). A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine 315, 552-8.
36. Freifeld, A. G., Walsh, T., Marshall, D., Gress, J., Steinberg, S. M., Hathorn, J. et al. (1995). Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. Journal of Clinical Oncology 13, 165-76.
37. De Pauw, B. E., Deresinski, S. C., Feld, R., Lane-Allman, E. F. & Donnelly, J. P. for the Intercontinental Antimicrobial Study Group. (1994). Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Annals of Internal Medicine 120, 834-44.
38. Elting, L. S. & Bodey, G. P. (1995). Outcomes of bacteremia in neutropenic cancer patients: influence of major organ or tissue infection. Supportive Care in Cancer 3, 331-3, Abstract no. 2.
39. Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R. et al. (1995). A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine 332, 1678-83.
40. Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paccuicci, P. A., Schulman, P. et al. (1995). Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine 332, 1671-7.
41. Vose, J. M. & Armitage, J. O. (1995). Clinical applications of hematopoietic growth factors. Journal of Clinical Oncology 13, 1023-35.
42. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. & Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-41.
43. Klastersky, J., Mommen, P., Cantraine, F. & Safary, A. (1986). Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. European Journal of Cancer and Clinical Oncology 22, 807-13.
44. Bron, D. (1995). Bone marrow transplantation. In Handbook of Supportive Care in Cancer (Klastersky, J., Schimpft, S. C. & Senn, H. J., Eds), pp. 491-510. Marcel Dekker, New York, NY.
45. Hardy, I., Ghershon, A. A., Steinberg, S. P. & LaRussa, P. (1991). The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. New England Journal of Medicine 325, 1545-50.
46. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H. et al. (1982). Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307, 1225-30.
47. Bowden, R. A., Fisher, L. D., Rogers, K., Cays, M. & Meyers, J. D. (1991). Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. Journal of Infectious Diseases 164, 483-7.
48. Chapel, H. M., Lee, M., Hargreaves, R., Pamphilon, D. H. & Prentice, A. G. for the UK Group for lmmunoglobulin Replacement Therapy in Multiple Myeloma. (1994). Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateauphase multiple myeloma. Lancet 343, 1059-63.
49. Sullivan, K. M., Kipecky, K. J., Jocom, J., Fisher, L., Buckner, C. D., Meyers, J. D. et al. (1990). Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. New England Journal of Medicine 323, 705-12.
50. Guiot, H. F. L., Fibbe, W. E. & van't Wout, J. W. (1994). Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clinical Infectious Diseases 18, 525-32.
51. Walsh, T. J., Hiemenz, J. & Pizzo, P. A. (1994). Evolving risk factors for invasive fungal infections - all neutropenic patients are not the same. Clinical Infectious Diseases 18, 793-8.
52. Klastersky, J. (1995). Therapy of infections in cancer patients. In Handbook of Supportive Care in Cancer (Klastersky, J., Schimpff, S. C. & Senn, H. J., Eds), pp. 1-44. Marcel Dekker, New York, NY.
53. Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R. et al. (1995). Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. Journal of Infectious Diseases 171, 1545-52.
54. EORTC International Antimicrobial Therapy Cooperative Group. (1989). Empiric antifungal therapy in febrile granulocytopenic patients. American Journal of Medicine 86, 668-72.
55. Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E. et al. (1994). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 331, 1325-30.
56. Tollemar, J., Ringden, O. & Tyden, G. (1990). Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clinical Transplantation 4, 167-75.
57. Bodey, G. P., Anaissie, E., Gutterman, J. & Vadhan-Raj, S. (1993). Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clinical Infectious Diseases 17, 705-7.
58. Klastersky, J. (1995). Prevention and therapy of fungal infections in cancer patients. A review of recently published information. Supportive Care in Cancer 3, 393-401.
59. Talcott, J. A., Siegel, R. D., Finberg, R. & Goldman, L. (1992). Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology 10, 316-22.
60. Talcott, J. A., Whalen, A., Clark, J., Rieker, P. P. & Finberg, R. (1994). Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a plot study of 30 patients based on a validated prediction rule. Journal of Clinical Oncology 12, 107-14.
61. Rubenstein, E. B. & Rolston, K. V. I. (1995). Outpatient treatment of febrile neutropenic patients with cancer. European Journal of Cancer 31A, 2-4.
62. Gilbert, C., Meisenberg, B., Bredenburgh, J., Ross, M., Hussein, A., Perfect, J. et al. (1994). Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. Journal of Clinical Oncology 12, 1005-11.
63. Gardembas-Pain, M., Desablens, B., Sensebe, L., Lamy, T., Ghandour, C. & Boasson, M. (1991). Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Annals of Oncology 2, 485-7.
64. Klastersky, J. (1993). Febrile neutropenia. Current Opinion in Oncology 5, 625-32.
65. Iomiak, A. T., Yau, J. C., Huan, S. D., Cripps, M. C., Goel, R., Perrault, D. J. et al. (1994). Duration of intravenous antibiotics for patients with neutropenic fever. Annals of Oncology 5, 441-5.